Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harmony Biosciences Holdings, Inc. filings document a commercial-stage pharmaceutical issuer focused on rare neurological diseases and its WAKIX-centered operating results. Form 8-K reports furnish quarterly and annual financial results, preliminary net product revenue, revenue guidance, investor presentations, and clinical-program updates.
Governance filings include definitive proxy materials for annual meeting matters, board elections, executive compensation, and shareholder voting procedures. Material-event reports also record executive appointments, separations, compensatory arrangements, board changes, Regulation FD disclosures, and exhibit-based updates related to the company’s business and pipeline.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to the exercise of options under a registered plan for 25,000 shares on 07/02/2026, to be settled for cash. The filing also lists multiple sales by Sandip Kapadia during June–July 2026, with recent transactions including 50,000 shares on 06/30/2026.
Sandip Kapadia reported transactions to sell up to 50,000 shares of Common Stock. The filing lists the method as an Exercise of Options Under a Registered Plan with cash settlement and names Morgan Stanley Smith Barney LLC as the broker.
The excerpt also discloses multiple sales by Sandip Kapadia in May and June 2026, with individual transactions and gross proceeds shown for each date.
HRMY affiliate files a notice of proposed sale under Form 144 for 45,594 shares. The filing states the disposition method as an exercise of options under a registered plan with cash proceeds, dated 06/26/2026. The excerpt also lists multiple sales by Sandip Kapadia totaling recent dispositions on 05/08/2026 through 06/24/2026.
Sandip Kapadia submitted a Form 144 notifying a proposed disposition of Common Stock under Rule 144. The filing lists Morgan Stanley Smith Barney LLC as the broker/agent and records recent dispositions: 45,481 shares (05/08/2026), 27,960 shares (06/09/2026), 7,064 shares (06/04/2026), and 2,101 shares (06/05/2026) with corresponding proceeds shown in the excerpt.
HRMY affiliate files Form 144 to report proposed and recent sales of Common Stock. The filing lists an exercise of options under a registered plan on 06/05/2026 for 27,960 shares and shows sales by Sandip Kapadia of 2,101 shares on 06/05/2026, 7,064 shares on 06/04/2026, and 45,481 shares on 05/08/2026 with cash proceeds reported for each transaction.
HRMY affiliate submitted a Rule 144 notice for proposed common stock sales related to option exercises on 06/05/2026.
The filing lists two recent dispositions: 7,064 shares sold on 06/04/2026 for $233,232.09 and 45,481 shares sold on 05/08/2026 for $1,433,056.28. The excerpt also shows 57,892,676 shares outstanding as of 06/05/2026.
Sandip Kapadia submitted a notice of proposed sale under Form 144 relating to Common Stock of HRMY. The filing records 45,481 shares sold on 05/08/2026 for an aggregate amount of $1,433,056.28. It also lists a planned transaction tied to an exercise of options under a registered plan dated 06/04/2026.
Harmony Biosciences Holdings, Inc. director Germano Geno J received a grant of stock options as equity compensation. The award covers 21,231 options for common stock at an exercise price of $30.76 per share and expires on May 14, 2036. These options vest in 36 equal monthly installments beginning on June 14, 2026. Following this grant, he holds 21,231 stock options directly, with no open-market share purchases or sales reported in this filing.
Harmony Biosciences Holdings, Inc. director Germano Geno J filed an initial Form 3, which is the SEC’s required first insider ownership report for company officers, directors, and large shareholders. This filing lists him as a reporting person but does not show any specific share transactions.
Harmony Biosciences Holdings, Inc. reported that director Linda M. Szyper received a grant of stock options covering 21,872 shares of common stock at an exercise price of $30.76 per share. These options expire on May 14, 2036 and represent compensation rather than an open‑market purchase.
The option vests in full on the earlier of May 14, 2027 or the date of the next annual meeting following the grant, as long as Szyper continues in service through that date. Following this award, she holds 21,872 derivative securities directly tied to Harmony Biosciences common stock.